ABBVNYSE
AbbVie Inc.
$0.00
0.000.00%
15-min delay
Open
Prev Close
Market Cap$450.11B
P/E (TTM)126.85
EPS$10.00
Earnings2026-07-31
DAY RANGE
$0.00$0.00
Company Info

AbbVie Inc. is a research-based biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines and therapies worldwide. The company maintains a strong focus on immunology, offering treatments like Humira, Skyrizi, and Rinvoq for autoimmune and inflammatory conditions in rheumatology, gastroenterology, dermatology, and related areas. In oncology, it provides therapies such as Imbruvica, Venclexta, Elahere, Epkinly, and Emrelis targeting blood cancers, lymphoma, and lung cancer. AbbVie Inc. also addresses virology with Mavyret for hepatitis C, neuroscience for neurological disorders like Parkinson's, and additional areas including metabolic diseases, cystic fibrosis complications, endometriosis pain, irritable bowel syndrome, chronic constipation, and pancreatic enzyme therapy with Creon, alongside aesthetics products like Botox and Linzess/Constella. Founded in 2013 and headquartered in North Chicago, Illinois, AbbVie Inc. plays a vital role in the healthcare sector by delivering solutions for complex, chronic, and serious health conditions.

Websiteabbvie.com
SectorHealth Technology
Employees57000
Phone847 932 7900
Address1 North Waukegan Road 11 Bermudiana Road
North Chicago, IL, 60064-6400
ISINUS00287Y1091
1 North Waukegan Road 11 Bermudiana Road, North Chicago, IL
Open in Maps
Key Statistics
Full Stats
Market Cap$450.11B
Enterprise Value$517.91B
P/E Ratio (TTM)126.85
P/S Ratio7.23
P/B Ratio
Forward P/E1.18
EPS (TTM)$2.03
EPS (FY)$10.00
Revenue (TTM)$62.82B
Profit Margin5.72%
Operating Margin33.58%
ROE15221.82%
Debt/Equity
Avg Vol (30d)7.9M
Beta (1Y)-0.45
Beta (3Y)0.16
Beta (5Y)0.28
Shares Out1.77B
Float1.76B
Dividend2.73%
Next Earnings2026-07-31
Short Interest
52-Week Range
$0.00
$187.62$261.64
Upgrades / Downgrades
Upgrades0
Maintained0
Downgrades0
Grades Consensus
Price Target Consensus
High
Low
Median
Current
Forward Estimates